Drug combination therapies are recognised as essential therapeutic treatments for infectious diseases, cancer & HIV/AIDS. They can enhance a clinical efficacy profile, improve the therapeutic window and delay the onset of acquired drug resistance.
In a recent study on digital health in the pharmaceutical industry, management consultancy Arthur D. Little provided an industry snapshot of pharmaceutical companiesâ goals for 2020 and their progress so far.
Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays and refinement of paradigms.
Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 to $4 billion.
15 years after being first described to occur in mammalian cells, numerous trials are indicating that RNA interference can be harnessed to treat human disease. This article argues that positive results are now starting to emerge .
By Dr C Landqvist, B Middleton, Dr B Jones, Dr C OâDonnell
An integral part of early drug discovery at AstraZeneca is the process known as the Design Make Test Analyse Cycle. DMTA relies heavily on chemical synthesis and primary screening being delivered within a quick turnaround time.